Literature DB >> 17245182

Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Paulus G Schurr1, Tim Strate, Kim Rese, Jussuf T Kaifi, Uta Reichelt, Susanne Petri, Helge Kleinhans, Emre F Yekebas, Jakob R Izbicki.   

Abstract

OBJECTIVE: To evaluate surgical strategies for neuroendocrine pancreatic tumors (NEPT) in the light of the new WHO classification from 2004 and to draw conclusions for future surgical concepts.
BACKGROUND: : The extent of surgical resection in primary and recurrent NEPT is unclear.
METHODS: Between 1987 and 2004, 62 patients with sporadic NEPT were treated at our institution and sections from biopsy and resection specimen were histopathologically reclassified. Clinical presentation, surgery, metastases, and pattern of recurrence were related to survival.
RESULTS: Fifteen well-differentiated tumors (WDT, 24%), 39 low-grade carcinomas (LGC, 63%), and 8 high-grade carcinomas (HGC, 13%) were identified. Median observation time was 30.5 months; 48 of 62 patients (78%) were surgically resected, and in 45 patients R0/R1 status was achieved. Overall 2- and 5-year survival in the latter group was 80% and 64%, respectively. Retrospective WHO classification revealed that organ-preserving segmental resections had been performed in 10 LGC and 1 HGC. These patients showed equal outcome as radically resected counterparts (n = 19). Liver and other organ metastases were present in 19 of 62 patients (31%), and resection was accomplished in 7 of 19 patients, which conferred better overall survival (P = 0.026, log-rank test); 21 of 45 R0/R1-resected patients (47%) suffered from recurrence, and reoperation was accomplished in 9 patients, which resulted in better overall survival (P = 0.066).
CONCLUSION: Organ-preserving resections offer sufficient local control in LGC; therefore, radical resections do not seem to be justified. On the other hand, radical resection is indicated even in metastasized patients or in case of loco-regional recurrence. The silent and slow course of the disease facilitates long-term surgical control.

Entities:  

Mesh:

Year:  2007        PMID: 17245182      PMCID: PMC1876988          DOI: 10.1097/01.sla.0000232556.24258.68

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  23 in total

1.  Chromogranins--new sensitive markers for neuroendocrine tumors.

Authors:  B Eriksson; H Arnberg; K Oberg; U Hellman; G Lundqvist; C Wernstedt; E Wilander
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

2.  Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.

Authors:  Quyen D Chu; Hank C Hill; Harold O Douglass; Deborah Driscoll; Judy L Smith; Hector R Nava; John F Gibbs
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy.

Authors:  P Kann; F Bittinger; M Engelbach; S Bohner; A Weis; J Beyer
Journal:  Eur J Med Res       Date:  2001-09-28       Impact factor: 2.175

5.  Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids.

Authors:  B Skogseid
Journal:  World J Surg       Date:  2001-06       Impact factor: 3.352

6.  Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients.

Authors:  B Eriksson; K Oberg; B Skogseid
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

7.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

8.  Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Authors:  Jeffrey A Norton; Maryann Kivlen; Michelle Li; Darren Schneider; Timothy Chuter; Robert T Jensen
Journal:  Arch Surg       Date:  2003-08

9.  Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center.

Authors:  Ulrich-Frank Pape; Michael Böhmig; Uta Berndt; Nikolaus Tiling; Bertram Wiedenmann; Ursula Plöckinger
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

Review 10.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

View more
  52 in total

1.  Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Authors:  David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

2.  Concomitant endometrial and pancreatic cancers.

Authors:  S Michelle Shiller; Shawna L Bull Phelps; Jeffrey P Lamont; Granger R Scruggs
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

3.  Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.

Authors:  Shaun McKenzie; Wendy Lee; Avo Artinyan; Brian Mailey; Alessio Pigazzi; Joshua Ellenhorn; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2010-05-18       Impact factor: 3.452

Review 4.  Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

Authors:  Diane Reidy-Lagunes; Raymond Thornton
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

6.  Pancreatic neuroendocrine tumours.

Authors:  J Ruiz-Tovar; P Priego; E Martínez-Molina; V Morales; A Sanjuanbenito; E Lobo
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

Review 7.  [Indications for surgical resection of benign pancreatic tumors].

Authors:  R Isenmann; D Henne-Bruns
Journal:  Radiologe       Date:  2008-08       Impact factor: 0.635

Review 8.  Laparoscopic resection of pancreatic neuroendocrine tumors.

Authors:  Abbas Al-Kurd; Katya Chapchay; Simona Grozinsky-Glasberg; Haggi Mazeh
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 9.  Neuroendocrine tumors of the pancreas.

Authors:  Karen Davies; Kevin C Conlon
Journal:  Curr Gastroenterol Rep       Date:  2009-04

10.  Consensus guidelines for the management and treatment of neuroendocrine tumors.

Authors:  Pamela L Kunz; Diane Reidy-Lagunes; Lowell B Anthony; Erin M Bertino; Kari Brendtro; Jennifer A Chan; Herbert Chen; Robert T Jensen; Michelle Kang Kim; David S Klimstra; Matthew H Kulke; Eric H Liu; David C Metz; Alexandria T Phan; Rebecca S Sippel; Jonathan R Strosberg; James C Yao
Journal:  Pancreas       Date:  2013-05       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.